Author | Robert A. Dowling, MD


Denosumab tops spending for common urology Part B drugs

June 16, 2020


Mitomycin sees the largest annual growth in spending per dose over the past 5 years, Robert A. Dowling, MD, reports.

Four lessons urology practices can learn from the pandemic

April 17, 2020


Replacing office visits with virtual visits may become the new normal, writes Robert A. Dowling, MD.

Utilization review data: How do payers view your practice?

April 07, 2020


"Many companies understand your utilization, payment, and prescribing data much more thoroughly than you might think," writes Robert A. Dowling, MD.

Can you afford to avoid MIPS participation?

January 31, 2020


"Ignoring the entire Quality category may be a risky strategy in 2020 and beyond," warns Robert A. Dowling, MD.